coli in Medical Technology

K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers' Grains

... team headed by Kansas State University E. coli O157:H7 expert T.G. Nagaraja has been tapped by ... between feeding distillers' grains and E. coli 0157:H7 in cattle and several strategies to ... between dietary distillers' grains and E. coli 0157:H7 in cattle, as well as provide us with an ...

Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050

... the clinic in 2009. Wacker's proprietary E. coli secretion system is a well-established technology ... At the core of the technology is a proprietary E. coli K12-strain, developed by Wacker, to secrete ... obtained to date underscore the power of our E. coli secretion technology and highlight Wacker ...

DuPont and USDA ARS to Collaborate on New E. coli Test in Beef

... DuPont Qualicon will develop a new test for E. coli 0157:H7, a pathogen that led to more than 30 ... president -- DuPont Qualicon, said. E. coli O157:H7 is a food borne pathogen usually ... pounds of ground beef recalled due to possible E. coli O157:H7 contamination. The award-winning ...

K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security

... April 2008. Nagaraja will present "Escherichia coli 0157 and Food Safety" at 9 a.m. He will discuss how Escherichia coli O157 has emerged as a major foodborne pathogen. Nagaraja studies the ecology of E. coli O157 in cattle and is working to identify ...

Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity

... (MIC) of clarithromycin for ESBL-producing strains of Escherichia coli by a factor of 250-750. NAB 739, the lead compound of the second series, ... efficacy of both lead compounds has been verified using an experimental E. coli peritonitis model in mice, and we are now talking to potential partners to ...

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine

... in the developing world, where diarrhea linked to enterotoxigenic E. coli -- the most common causes of travelers' diarrhea -- sickens 210 million ... evaluate the safety of the vaccine and the incidence of enterotoxigenic E. coli (ETEC) bacteria - the most common cause of travelers' diarrhea. No ...

Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist

... Dr. Nash developed quick swab tests to detect Listeria in feedlots and E. coli in processing plants. Dr. Nash also developed tests for strep, whooping ... Nash designed all-natural cattle feed additives to inhibit a dangerous E. coli 1057:H7 strain and improve feed efficiency with "impressive results." Dr. ...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

... The July issue of Mayo Clinic Women's HealthSource provides an overview of food storage safety and how to avoid bad bacteria, such as E. coli and salmonella. Safe food storage matters. While diarrhea and vomiting caused by food poisoning usually resolve without treatment, about ...

Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets

... ATLANTA, Feb. 10 /PRNewswire/ -- Food retailers concerned about pathogens such as Salmonella, Listeria, and E. coli in their perishable departments can now outsource "deep cleaning" services to Chemstar Corporation, a company that operates food safety and ...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... delivery of the active hairpin RNA component by the bacterial system. Cequent developed the current tk RNAi candidate on the basis of an E. coli delivery platform obtained from the laboratory of Patrice Courvalin at the Institut Pasteur. Cequent is planning to start a Phase I clinical trial ...

GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.

... other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, Chronic Wasting Disease, E. coli 0157:H7 and Johne's disease, all diseases affecting cattle worldwide. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith ...

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... including MRSA, penicillin-resistant Streptococcus pneumoniae (PRSP), vancomycin-resistant Enterococcus (VRE), multidrug resistant Escherichia coli and other difficult-to-treat pathogens. Introduced more than 50 years ago, tetracyclines remain among the most commonly used antiinfective agents to ...

Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008

... how to deliver the molecules triggering RNAi into the target cells and diseased tissues. In a proprietary process, we modify live, nonpathogenic E. coli bacteria to produce and deposit mediators of RNA interference (short hairpin RNA) directly into the target cells. The nonpathogenic bacteria are ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.

... of human food and water supplies. Its most significant initiative is a vaccine that, when administered to cattle, reduces the level of Escherichia coli (E. coli) O157:H7 that can be shed into the environment, thereby seeking to reduce human illnesses from contaminated food and water. The vaccine has ...

Increasing Dairy Milk Production with Electrolyzed Drinking Water

... collected from the troughs over the course of the study showed the EAU treated water was consistently negative for coliform organisms such as E. coli and other bacteria. Blood chemistry tests conducted also showed that blood urea nitrogen, creatinine, magnesium and chloride levels were lower in ...

Congressional Funds Awarded for Testing of Antimicrobial Copper Metals

... greatly to reduce the spread of certain virulent, antibiotic-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and E. coli O157:H7." The clinical trials follow peer-reviewed research conducted at the University of Southampton in the U.K. proving copper, brass and bronze ...

Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... and Co-Founder of Paratek. In addition, Paratek announced a newly released publication showing efficacy of the Company's MAR inhibitors against E. coli in urinary tract infection in another animal model of serious bacterial infection. The article, titled, "Novel anti-infection agents: Small-molecule ...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA

... methicillin-susceptible S. aureus (MSSA) (91% vs. 92%, respectively); MRSA (87% vs. 86%); S. pyogenes (90% vs. 100%); S. agalactiae (81% vs. 75%); E. coli (86% vs. 92%); P. aeruginosa (83% vs. 89%); and, Enterobacter spp., Klebsiella pneumoniae, and Proteus mirabilis (86% vs. 83%) from the site of ...

Iomai Announces Data from Phase 2 Field Study of Travelers' Diarrhea Vaccine Accepted for Presentation at ICAAC

... to be held in Chicago Sept. 17 to 20. The abstract, "Transcutaneous Immunization with the Heat Labile Toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) Protects in a Phase 2 Field Trial in Travelers to Guatemala and Mexico," will be presented by Gregory Glenn, M.D., Iomai's chief scientific ...

Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals

... pathogens which are the source of many hospital- acquired infections, including methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli O157:H7. The U.S. Centers for Disease Control and Prevention (CDC) estimates that infections acquired in U.S. hospitals affect some two million ...

Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University

... on the study. "Based on the success of this translational work, Vaxiion is developing a multi-component vaccine against Salmonella, Shigella and E. coli for use in human clinical trials," Sabbadini said. Other co-authors of the study include Yen-Lin Chu of SDSU; Neil L. Berkley, co-founder of ...

Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322

... with properties of successful drugs, including high potency, specificity, stability, favorable half life, favorable IP profile and high yield E. coli production. Adnectins are designed using the PROfusion System, Adnexus' patented protein design engine, to achieve high potency and specificity for ...

Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

... diarrhea. The trial was conducted to assess the ability of a range of vaccine doses to generate an immune response against enterotoxigenic E. coli (ETEC) bacteria -- the most common cause of travelers' diarrhea. Researchers found that even at the lowest dose tested, an Iomai patch applied to the ...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

... market growth; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other preclinical and clinical testing; (5) the ability to negotiate strategic partnerships or other disposition transactions for AVANT's ...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

... and further development, including animal, pre-clinical and clinical studies, and commercialization of CholeraGarde® (Peru-15), Ty800, ETEC E. coli vaccine, VLPs and other products and AVANT’s expectations regarding market growth; (4) the cost, timing, scope and results of ongoing ...

Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO

... and oncology. Thallion’s clinical-stage programs include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anticancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with ...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

... strand polymerase, followed slightly thereafter by replication of the lagging strand by a different polymerase. In lower organisms like the E. coli bacteria that Kornberg studied, one DNA polymerase can accomplish both tasks. However, humans and related higher organisms, such as bakers yeast, are ...